U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $159.43, a high estimate of $160.00 ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

Novo Nordisk's involve the GLP-1 pathway ... which was evident at the recent ObesityWeek 2024, an annual meeting highlighting ...

Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...

In recent health news, Chinese scientists stress the need for regional diets to combat obesity, U.S. minority veterans ...

told the meeting that the promising results justify further research and a larger phase 2 trial is planned for the second half of this year, with results expected in around 2026. Novo Nordisk’s ...

We hope the weekend respite was relaxing and invigorating, because that oh-so predictable routine of online meetings, phone ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

The Department of Health & Family Welfare, Nagaland held a consultative meeting with members of Novo Nordisk Foundation (NNF) ...

Oct 21 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said ... by 14% compared to placebo, meeting the main goal of the trial. The study tested the drug as an adjunct to standard of care ...